265 related articles for article (PubMed ID: 18579112)
61. Immunosuppressive therapy for ocular mucous membrane pemphigoid strategies and outcomes.
Saw VP; Dart JK; Rauz S; Ramsay A; Bunce C; Xing W; Maddison PG; Phillips M
Ophthalmology; 2008 Feb; 115(2):253-261.e1. PubMed ID: 17655931
[TBL] [Abstract][Full Text] [Related]
62. Efficacy and safety of daclizumab induction for primary kidney transplant recipients in combination with tacrolimus, mycophenolate mofetil, and steroids as maintenance immunosuppression.
Ciancio G; Burke GW; Suzart K; Vaidya A; Roth D; Kupin W; Mattiazzi A; Rosen A; Esquenazi V; Miller J
Transplant Proc; 2003 Mar; 35(2):873-4. PubMed ID: 12644172
[No Abstract] [Full Text] [Related]
63. Two-dose daclizumab induction therapy in 209 liver transplants: a single-center analysis.
Sellers MT; McGuire BM; Haustein SV; Bynon JS; Hunt SL; Eckhoff DE
Transplantation; 2004 Oct; 78(8):1212-7. PubMed ID: 15502722
[TBL] [Abstract][Full Text] [Related]
64. Daclizumab induction as an immunosuppressive regimen for renal transplant recipients from non-heart-beating donors.
Sánchez-Fructuoso AI; Prats D; Marques M; Ridao N; Conesa J; García Mena M; Torrente J; Barrientos A
Transplant Proc; 2003 Aug; 35(5):1689-90. PubMed ID: 12962759
[TBL] [Abstract][Full Text] [Related]
65. [Immunosuppressive therapy with mycophenolate mofetil (CellCept) in treatment of uveitis].
Zierhut M; Stübiger N; Aboalchamat W; Landenberger H; Bialasiewicz AA; Engelmann K
Ophthalmologe; 2001 Jul; 98(7):647-51. PubMed ID: 11490743
[TBL] [Abstract][Full Text] [Related]
66. Randomized trial of mycophenolate mofetil versus enteric-coated mycophenolate sodium in primary renal transplant recipients given tacrolimus and daclizumab/thymoglobulin: one year follow-up.
Ciancio G; Burke GW; Gaynor JJ; Roth D; Sageshima J; Kupin W; Tueros L; Hanson L; Rosen A; Ruiz P; Miller J
Transplantation; 2008 Jul; 86(1):67-74. PubMed ID: 18622280
[TBL] [Abstract][Full Text] [Related]
67. [Daclizumab in combination with mycophenolate mofetil and a late introduction of Tacrolimus at low doses, as a therapeutic approach in the elderly renal transplant donor-recipients pairs in kidney transplant].
Gentil MA; Osuna A; Capdevilla L; Cantarell C; Pereira P; Mazuecos A; González Molina M
Nefrologia; 2008; 28(3):287-92. PubMed ID: 18590495
[TBL] [Abstract][Full Text] [Related]
68. Current immunosuppressive agents in pediatric renal transplantation: efficacy, side-effects and utilization.
Smith JM; Nemeth TL; McDonald RA
Pediatr Transplant; 2004 Oct; 8(5):445-53. PubMed ID: 15367279
[TBL] [Abstract][Full Text] [Related]
69. Toxicity-sparing protocols using mycophenolate mofetil in renal transplantation.
Land W; Vincenti F
Transplantation; 2005 Oct; 80(2 Suppl):S221-34. PubMed ID: 16251855
[TBL] [Abstract][Full Text] [Related]
70. Immunomodulatory therapy for ocular inflammatory disease: a basic manual and review of the literature.
Okada AA
Ocul Immunol Inflamm; 2005; 13(5):335-51. PubMed ID: 16419419
[TBL] [Abstract][Full Text] [Related]
71. New immunosuppressants in BMT/GVHD.
Basara N; Günzelmann S; Willenbacher W; Fauser AA; Kiehl MG
Transplant Proc; 2001 May; 33(3):2220-2. PubMed ID: 11377507
[No Abstract] [Full Text] [Related]
72. Initial clinical experience with interleukin-2 receptor antagonist induction in combination with tacrolimus, mycophenolate mofetil and steroids in simultaneous kidney-pancreas transplantation.
Lo A; Stratta RJ; Alloway RR; Egidi MF; Shokouh-Amiri MH; Grewal HP; Gaber LW; Gaber AO
Transpl Int; 2001 Dec; 14(6):396-404. PubMed ID: 11793037
[TBL] [Abstract][Full Text] [Related]
73. Daclizumab induction for primary kidney transplant recipients using tacrolimus, mycophenolate mofetil, and steroids as maintenance immunosuppression.
Ciancio G; Miller A; Burke GW; Gharagozloo H; Rosen A; Roth D; Kupin W; Pinna A; Cespedes M; Esquenazi V; Miller J
Transplant Proc; 2001; 33(1-2):1013-4. PubMed ID: 11267169
[No Abstract] [Full Text] [Related]
74. Results of 3-year phase III clinical trials with daclizumab prophylaxis for prevention of acute rejection after renal transplantation.
Bumgardner GL; Hardie I; Johnson RW; Lin A; Nashan B; Pescovitz MD; Ramos E; Vincenti F;
Transplantation; 2001 Sep; 72(5):839-45. PubMed ID: 11571447
[TBL] [Abstract][Full Text] [Related]
75. Daclizumab induction and maintenance steroid-free immunosuppression with mycophenolate mofetil and tacrolimus to prevent acute rejection of hepatic allografts.
Figueras J; Prieto M; Bernardos A; Rimola A; Suárez F; de Urbina JO; Cuervas-Mons V; Mata Mde L
Transpl Int; 2006 Aug; 19(8):641-8. PubMed ID: 16827681
[TBL] [Abstract][Full Text] [Related]
76. Calcineurin inhibitor avoidance with daclizumab, mycophenolate mofetil, and prednisolone in DR-matched de novo kidney transplant recipients.
Asberg A; Midtvedt K; Line PD; Narverud J; Holdaas H; Jenssen T; Reisaeter AV; Johnsen LF; Fauchald P; Hartmann A
Transplantation; 2006 Jul; 82(1):62-8. PubMed ID: 16861943
[TBL] [Abstract][Full Text] [Related]
77. Analysis of malignancies in patients after heart transplantation with subsequent immunosuppressive therapy.
Rivinius R; Helmschrott M; Ruhparwar A; Schmack B; Klein B; Erbel C; Gleissner CA; Akhavanpoor M; Frankenstein L; Darche FF; Thomas D; Ehlermann P; Bruckner T; Katus HA; Doesch AO
Drug Des Devel Ther; 2015; 9():93-102. PubMed ID: 25552900
[TBL] [Abstract][Full Text] [Related]
78. Two-dose basiliximab compared with two-dose daclizumab in renal transplantation: a clinical study.
Lin M; Ming A; Zhao M
Clin Transplant; 2006; 20(3):325-9. PubMed ID: 16824149
[TBL] [Abstract][Full Text] [Related]
79. A randomized trial of three renal transplant induction antibodies: early comparison of tacrolimus, mycophenolate mofetil, and steroid dosing, and newer immune-monitoring.
Ciancio G; Burke GW; Gaynor JJ; Carreno MR; Cirocco RE; Mathew JM; Mattiazzi A; Cordovilla T; Roth D; Kupin W; Rosen A; Esquenazi V; Tzakis AG; Miller J
Transplantation; 2005 Aug; 80(4):457-65. PubMed ID: 16123718
[TBL] [Abstract][Full Text] [Related]
80. Mycophenolate mofetil therapy for inflammatory eye disease.
Thorne JE; Jabs DA; Qazi FA; Nguyen QD; Kempen JH; Dunn JP
Ophthalmology; 2005 Aug; 112(8):1472-7. PubMed ID: 16061096
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
